Search

01/06/2022 Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
Waszczuk-Gajda, A, Penack, O, Sbianchi, G, Koster, L, Blaise, D, Remenyi, P, Russell, N, Ljungman, P, Trneny, M, Mayer, J, Iacobelli, S, Kobbe, G, Scheid, C, Apperley, J, Touzeau, C, Lenhoff, S, Jantunen, E, Anagnostopoulos, A, Paris, L, Browne, P, Thieblemont, C, Schaap, N, Sierra, J, Yakoub-Agha, I, Garderet, L, Styczynski, J, Schoemans, H, Moiseev, I, Duarte, RF, Peric, Z, Montoto, S, van Biezen, A, Mikulska, M, Aljurf, M, Ruutu, T, Kroger, N, Morris, C, Koenecke, C, Schoenland, S, Basak, GW. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine. 2022; 11(12)DOI:10.3390/jcm11123541. PMID:35743620. IF:3.900(Q2/4D).
07/05/2022 SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Pinana, JL, Lopez-Corral, L, Martino, R, Vazquez, L, Perez, A, Martin-Martin, G, Gago, B, Sanz-Linares, G, Sanchez-Salinas, A, Villalon, L, Conesa-Garcia, V, Olave, MT, Corona, M, Marcos-Corrales, S, Tormo, M, Hernandez-Rivas, JA, Montoro, J, Rodriguez-Fernandez, A, Risco-Galvez, I, Rodriguez-Belenguer, P, Hernandez-Boluda, JC, Garcia-Cadenas, I, Ruiz-Garcia, M, Munoz-Bellido, JL, Solano, C, Cedillo, A, Sureda, A, Navarro, D. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology & Oncology. 2022; 15(1)DOI:10.1186/s13045-022-01275-7. PMID:35526045. IF:28.500(Q1/1D).
01/05/2022 Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
Garcia-Fortes, M, Hernandez-Boluda, JC, Alvarez-Larran, A, Raya, JM, Angona, A, Estrada, N, Fox, L, Cuevas, B, Garcia-Hernandez, MC, Gomez-Casares, MT, Ferrer-Marin, F, Saavedra, S, Cervantes, F, Garcia-Delgado, R. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 2022; 14(9)DOI:10.3390/cancers14092331. PMID:35565461. IF:5.200(Q2/3D).
01/05/2022 Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers
Arranz, MJ, Salazar, J, Bote, V, Artigas-Baleri, A, Serra-LLovich, A, Trivino, E, Roige, J, Lombardia, C, Cancino, M, Hernandez, M, Cendros, M, Duran-Tauleria, E, Maraver, N, Hervas, A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. Pharmaceutics. 2022; 14(5)DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5.400(Q1/2D).
01/05/2022 Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Reinoso-Segura, M, Caballero-Velazquez, T, Herrera, P, Patriarca, F, Fanin, R, Bruno, B, Einsele, H, Nahi, H, Granell, M, Lopez-Corral, L, Reguera, JL, Garcia-Cadenas, I, Gahrton, G, Perez-Simon, JA. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation And Cellular Therapy. 2022; 28(5)DOI:10.1016/j.jtct.2022.01.026. PMID:35131486. IF:3.200(Q2/5D).
25/04/2022 Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Orgueira, AM, Perez, MSG, Arias, JD, Rosinol, L, Oriol, A, Teruel, AI, Lopez, JM, Palomera, L, Granell, M, Blanchard, MJ, de la Rubia, J, de la Guia, AL, Rios, R, Sureda, A, Hernandez, MT, Bengoechea, E, Calasanz, MJ, Gutierrez, N, Martin, ML, Blade, J, Lahuerta, JJ, San Miguel, J, Mateos, MV. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00647-z. PMID:35468898. IF:12.800(Q1/1D).
19/04/2022 A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, C, Hernandez-Rivas, JA, Oriol, A, Rosinol, L, Blanchard, MJ, Bellon, JM, Garcia-Sanz, R, de la Rubia, J, de la Guia, AL, Jimenez-Ubieto, A, Jarque, I, Inigo, B, Dourdil, V, de Arriba, F, Perez-Avila, CC, Gonzalez, Y, Hernandez, MT, Bargay, J, Granell, M, Rodriguez-Otero, P, Silvent, M, Cabrera, C, Rios, R, Alegre, A, Gironella, M, Gonzalez, MS, Sureda, A, Sampol, A, Ocio, EM, Krsnik, I, Garcia, A, Garcia-Mateo, A, Soler, JA, Martin, J, Arguinano, JM, Mateos, MV, Blade, J, San-Miguel, JF, Lahuerta, JJ, Martinez-Lopez, J. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00652-2. PMID:35440057. IF:12.800(Q1/1D).
01/03/2022 Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients
Ramos-Campoy, S, Puiggros, A, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Ortega, M, Blanco, ML, Collado, R, Salgado, R, Baumann, T, Gimeno, E, Moreno, C, Bosch, F, Calvo, X, Calasanz, MJ, Cuneo, A, Strefford, JC, Nguyen-Khac, F, Oscier, D, Haferlach, C, Schoumans, J, Espinet, B. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. HAEMATOLOGICA. 2022; 107(3)DOI:10.3324/haematol.2020.274456. PMID:33691382. IF:10.100(Q1/2D).
01/01/2022 Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges
Redondo, S, Esquirol, A, Novelli, S, Caballero, AC, Garrido, A, Onate, G, Lopez, J, Moreno, C, Saavedra, SD, Granell, M, Briones, J, Sierra, J, Martino, R, Garcia-Cadenas, I. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation And Cellular Therapy. 2022; 28(1)DOI:10.1016/j.jtct.2021.10.015. PMID:34757054. IF:3.200(Q2/5D).
01/12/2024 Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation
Redondo, S, Garcia-Cadenas, I, Esquirol, A, Portos, JM, Iranzo, E, Arguello-Tomas, M, Saavedra, S, Oñate, G, Caballero, AC, Garrido, A, López, J, Muntañola, A, Paviglianiti, A, Miqueleiz, S, Sierra, J, Briones, J, Martino, R. Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation. EUROPEAN JOURNAL OF HAEMATOLOGY. 2024; 113(6)DOI:10.1111/ejh.14294. PMID:39155459. IF:2.300(Q2/5D).
01/10/2024 Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil
Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.07.027. PMID:39116938. IF:4.400(Q1/1D).
14/09/2024 Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Salas, MQ, Cascos, E, López-García, A, Pérez-López, E, Baile-González, M, López-Corral, L, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Ormtegi, IO, Marin, AJS, Peña-Muñóz, F, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, González-Rodríguez, AP, Torrado, T, García, L, Filaferro, S, Cedillo, A, Basalobre, P, Ortí, G, Chacón, MJ. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2024; 59(12)DOI:10.1038/s41409-024-02414-z. PMID:39277653. IF:5.200(Q1/1D).
31/08/2024 Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
Piñana, JL, Giménez, E, Vázquez, L, Marcos, MA, Guerreiro, M, Duarte, R, Pérez, A, de Miguel, C, Espigado, I, González-Vicent, M, Suarez-Lledó, M, García-Cadenas, I, Martino, R, Cedillo, A, Rovira, M, de la Cámara, R, Navarro, D, Solano, C. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC). Mediterranean Journal of Hematology and Infectious Diseases. 2024; 16(1)DOI:10.4084/MJHID.2024.065. PMID:39258183. IF:1.500(Q3/8D).
24/06/2024 Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies
Fox, ML, García-Cadenas, I, Navarro, V, Martínez, AP, Kara, M, Bazán, IS, Coll, CF, Bailén, R, Bento, L, Parody, R, Esquirol, A, Orti, G, Mussetti, A, Salamero, O, Martino, R, González, AP, Barba, P, Kwon, M, Solano, C, Bosch, F, Valcárcel, D. Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies. BONE MARROW TRANSPLANTATION. 2024; 59(10)DOI:10.1038/s41409-024-02322-2. PMID:38914883. IF:5.200(Q1/1D).
19/06/2024 Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Pinana, JL, Vazquez, L, Heras, I, Aiello, TF, López-Corral, L, Arroyo, I, Soler-Espejo, E, García-Cadenas, I, Garcia-Gutierrez, V, Aroca, C, Chorao, P, Olave, MT, Lopez-Jimenez, J, Gómez, MA, Arellano, E, Cuesta-Casas, M, Avendano-Pita, A, González-Santillana, C, Hernández-Rivas, JA, Roldán-Perez, A, Mico-Cerdá, M, Guerreiro, M, Morell, J, Rodriguez-Galvez, P, Labrador, J, Campos, D, Cedillo, A, Vidal, CG, Martino, R, Solano, C. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1389345. PMID:39015498. IF:3.300(Q2/4D).
01/05/2024 Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022.
Aerts R, Mehra V, Groll AH, Martino R, Lagrou K, Robin C, Perruccio K, Blijlevens N, Nucci M, Slavin M, Bretagne S, Cordonnier C. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022.. LANCET INFECTIOUS DISEASES. 2024; 24(5)DOI:10.1016/S1473-3099(23)00495-4. PMID:38134949. IF:31.000(Q1/1D).
01/05/2024 Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Drozd-Sokolowska, J, Gras, L, Koster, L, Martino, R, Salas, MQ, Salmenniemi, U, Zudaire, T, Yañez, L, Bellido, M, Collin, M, Kaufmann, M, Kozlowski, P, Poiré, X, Ferra, C, Sampol, A, Wilson, KMO, Cairoli, A, Gedde-Dahl, T, Deconinck, E, Mirabile, M, Suarez, F, Raj, K, van Gelder, M, Yakoub-Agha, I, Tournilhac, O, Mclornan, DP. Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. HAEMATOLOGICA. 2024; 109(5)DOI:10.3324/haematol.2023.284359. PMID:38205539. IF:10.100(Q1/2D).
01/12/2023 Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
Bastos-Oreiro M., Gutierrez A., Iacoboni G., López Corral L., Reguera J.L., Abrisqueta P., Delgado J., Terol M.J., Hernani R., Martínez N., Ortíz V., Bailen R., Gomez-Centurión I., Caballero A., Sanz J., Guerra Domínguez L., Luzardo H., Mussetti A., Jiménez-Ubieto A., Sancho J.M., Sureda A., Pérez A., Barba P., Kwon M., Martín García-Sancho A.. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. Transplantation And Cellular Therapy. 2023; 29(12)DOI:10.1016/j.jtct.2023.08.026. PMID:37659694. IF:3.600(Q1/3D).
01/12/2023 Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
Arqueros, C, Salazar, J, Gallardo, A, Andrés, M, Tibau, A, Bell, OL, Artigas, A, Lasa, A, Cajal, T, Lerma, E, Barnadas, A. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients. Biomedicines. 2023; 11(12)DOI:10.3390/biomedicines11123231. PMID:38137452. IF:3.900(Q1/3D).
16/11/2023 Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience
Esquirol, A, Cadenas, IG, Novelli, S, Garrido, A, Caballero, AC, Oñate, G, Lopez, J, Redondo, S, Argüello, M, Saavedra, S, Moreno, C, Briones, J, Sierra, J, Martino, R. Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience. ANNALS OF HEMATOLOGY. 2023; 103(1)DOI:10.1007/s00277-023-05530-w. PMID:37971549. IF:3.000(Q2/4D).